"Macmillan's research provides further evidence of how badly people with pancreatic cancer fare compared to other cancer patients. Pancreatic Cancer UK fully supports Macmillan's call for greater investment in research and care for cancer patients - especially those affected by pancreatic cancer, which has the worst survival rates. Median cancer survival rates for pancreatic cancer patients will only extend from months to years if there is a greater focus on how to diagnose and treat the disease more effectively, as identified in Pancreatic Cancer UK's Study for Survival."
Alex Ford, Chief Executive, Pancreatic Cancer UK
To read the full article, to which this responds, please click on the below links:
* Cancer survival: Macmillan hails major improvement (BBC News)